<DOC>
	<DOCNO>NCT00303771</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin , irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) different dos combination may kill tumor cell . It yet know combination chemotherapy regimen effective treat colorectal cancer . PURPOSE : This randomized clinical trial study well fluorouracil work together leucovorin without irinotecan treat old patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy First-Line Therapy Treating Older Patients With Metastatic Colorectal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival elderly patient unresectable metastatic colorectal cancer treat 1 2 different chemotherapy regimen comprise fluorouracil leucovorin calcium v without irinotecan hydrochloride . Secondary - Compare tumor response rate overall survival patient treat regimen . - Compare tolerability regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter , prospective study . Patients stratify accord participate center , gender , Karnofsky score ( 60-70 % vs 80-90 % vs 100 % ) , associate comorbidities ( Charlson Index 0 v 1-2 v 3+ ) , age ( 75 79 year vs ≥ 80 year ) , alkaline phosphatase level ( ≤ 2 time normal vs &gt; 2 time normal ) , prior adjuvant chemotherapy ( yes v ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive leucovorin calcium IV 2 hour fluorouracil IV continuously 22 hour day 1 2 . - Arm II : Patients receive leucovorin calcium IV 2 hour fluorouracil IV continuously 46 hour day 1 2 . - Arm III : Patients receive leucovorin calcium fluorouracil arm I irinotecan hydrochloride IV 90 minute day 1 . - Arm IV : Patients receive leucovorin calcium fluorouracil arm II irinotecan hydrochloride arm III . In arm , treatment repeat every 14 day absence disease progression unacceptable toxicity . Patients undergo surgery within 3-10 week complete chemotherapy . Quality life assess baseline every 2 month thereafter . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 282 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Metastatic disease Unresectable disease Measurable disease outside field prior irradiation No brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Transaminases ≤ 5 time normal Bilirubin ≤ 1.5 time normal Alkaline phosphatase &lt; 3 time normal ( 5 time normal due hepatic involvement ) Creatinine clearance &gt; 45 mL/min Life expectancy &gt; 3 month No psychological , social , geographical situation would preclude study treatment No chronic diarrhea enteropathy No coronary insufficiency symptomatic cardiac disease No malignancy unless curatively treat No contraindication chemotherapy PRIOR CONCURRENT THERAPY : At least 6 month since prior adjuvant chemotherapy primary tumor No prior extensive resection No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>